Advertisement
Screener

ADAGE CAPITAL PARTNERS GP, L.L.C. Historic Quarter Change: Foreign ADRs, Added

ADAGE CAPITAL PARTNERS GP, L.L.C. historic quarter change: Foreign ADRs, Added

In depositary receipts for foreign shares (depositary receipts and foreign shares traded over the counter), over 24 quarters from 2013-03-31 to 2026-06-30, ADAGE CAPITAL PARTNERS GP, L.L.C. opened 32 positions, added to 13, reduced 14 and sold out of 30.

  • Q3 2025: Stock ASTRAZENECA PLC; Country of operation —; Class SPONSORED ADR; Shares before 325,391.
  • Q2 2025: Stock ASCENDIS PHARMA A/S; Country of operation —; Class SPONSORED ADR; Shares before 327,405.
  • Q1 2025: Stock ASTRAZENECA PLC; Country of operation —; Class SPONSORED ADR; Shares before 353,438.
  • Q2 2024: Stock ASCENDIS PHARMA A/S; Country of operation —; Class SPONSORED ADR; Shares before 209,512.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1165408), 24 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-17); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-15); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-16); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-16); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-14); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-17); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-02-14); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-11-14); Q2 2013 (2013-03-31 to 2013-06-30, filed 2013-08-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2001-12-31. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).

QuarterStockCountry of operationClassShares beforeShares afterShare changeValue beforeValue afterValue changeFiled
Q3 2025ASTRAZENECA PLC
CUSIP 046353108
SPONSORED ADR325,391672,943+347,552$22,738,323$51,628,187+$28,889,8642025-11-14
Q2 2025ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR327,405459,606+132,201$51,029,343$79,327,996+$28,298,6532025-08-14
Q1 2025ASTRAZENECA PLC
CUSIP 046353108
SPONSORED ADR353,438647,271+293,833$23,157,258$47,574,419+$24,417,1612025-05-15
Q2 2024ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR209,512820,512+611,000$31,671,929$111,901,427+$80,229,4982024-08-14
Q1 2024AVADEL PHARMACEUTICALS PLC
CUSIP 05337M104
SPONSORED ADR225,0001,910,983+1,685,983$3,177,000$32,276,503+$29,099,5032024-05-15
Q1 2024ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR144,000209,512+65,512$18,136,800$31,671,929+$13,535,1292024-05-15
Q3 2016ANGLOGOLD ASHANTI LTD
CUSIP 035128206
SPONSORED ADR300,0001,300,000+1,000,000$5,418,000$20,696,000+$15,278,0002016-11-14
Q2 2016ROYAL DUTCH SHELL PLC
CUSIP 780259206
SPONS ADR A750,0001,317,228+567,228$36,338,000$72,737,000+$36,399,0002016-08-15
Q1 2016ROYAL DUTCH SHELL PLC
CUSIP 780259206
SPONS ADR A396,922750,000+353,078$18,175,000$36,338,000+$18,163,0002016-05-16
Q1 2014SHIRE PLC
CUSIP 82481R106
SPONSORED ADR50,671114,171+63,500$7,159,000$16,958,000+$9,799,0002014-05-15
Q1 2014AMARIN CORP PLC
CUSIP 023111206
SPONS ADR NEW800,0002,000,000+1,200,000$1,576,000$3,620,000+$2,044,0002014-05-15
Q4 2013VODAFONE GROUP PLC NEW
CUSIP 92857W209
SPONS ADR NEW200,000255,000+55,000$7,036,000$10,024,000+$2,988,0002014-02-14
Q4 2013AMARIN CORP PLC
CUSIP 023111206
SPONS ADR NEW300,000800,000+500,000$1,896,000$1,576,000-$320,0002014-02-14

Similar Firms

Firm NameCountry13F ValueHoldings
Baird Financial Group, Inc.United States$64.010B3,212
RENAISSANCE TECHNOLOGIES LLCUnited States$63.930B3,213
Assenagon Asset Management S.A.Luxembourg$65.872B1,095
GQG Partners LLCUnited States$63.092B86
CAISSE DE DEPOT ET PLACEMENT DU QUEBECCanada$62.433B684
Artisan Partners Limited PartnershipUnited States$62.336B334
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDCanada$62.212B1,469
ProShare Advisors LLCUnited States$67.536B1,865
MERCER GLOBAL ADVISORS INC /ADVUnited States$67.579B3,217
MITSUBISHI UFJ FINANCIAL GROUP INCUnited States$62.057B1